6月3日 - ** 癌症疗法开发商Agenus AGEN.O的股价盘前上涨33.4%至5.51美元
** AGEN和总部位于印度的Zydus Lifesciences ZYDU.NS达成了一项1.41亿美元的合作协议， (link)，以推进癌症免疫疗法药物的开发。
** 双方表示，Agenus公司将从Zydus公司获得750万美元的预付款，并有可能从Zydus公司获得5000万美元，用于转让其生物制剂生产设施。
** Zydus 将向 Agenus 投资 1600 万美元，以每股 7.50 美元的价格购买其股票。
** 截至上次收盘，AGEN 年累计上涨 50.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.